Continuous non chronomodulated infusion of floxuridine in metastatic renal cell carcinoma (MRCC): Report of 17 cases

Tumori

Volumn 82, Issue 3, 1996, Pages 225-227

  Baiocchi, Claudia ^a   Landonio, Giuseppe ^a   Cacioppo, Carlo ^a   Calgaro, Mario ^a   Cattaneo, Daniela ^a   Ferrari, Massimo ^a   Majno, Margherita ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

FUDR; infusion; MRCC

Indexed keywords

FLOXURIDINE;

ADULT; ANEMIA; ARTICLE; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MUCOSA INFLAMMATION; PATIENT SELECTION; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; FEMALE; FLOXURIDINE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED;

EID: 0029957050     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Baiocchi C., Landonio G., Balzarini G., Cacioppo C., Calgaro M., Ferrari M., Ghislandi E., Gottardi O., Majno M., Scanzi F., Brando B.: Possible correlation between some biological effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus alpha-2 interferon for metastatic renal cell carcinoma. Tumori, 80: 348-352, 1994.
2. Conroy T., Geoffrois L., Guillemin F., Luporsi E., Krakowski I., Spaeth D., Frasie V., Volff V.: Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer, 72: 2190-2197, 1993.
3. Damascelli B., Marchiano A., Spreafico C., Lutman R., Salvetti M., Bonalumi M.G., Mauri M., Garbagnati F., Del Nero A., Comeri G.: Circadian continuous chemotherapy of renal cell carcinoma with an implantable programmable infusion pump. Cancer, 66: 237-241, 1990.
4. Damascelli B., Marchiano A., Frigerio L.F., Salvetti M., Spreafico C., Garbagnati F., Zanoni F., Radice F.: Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma. Cancer, 68: 995-998, 1991.
5. Dexeus F.H., Logothetis C.J., Sella A., Amato R., Kilbourn R., Ogden S.: Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J. Uril., 146: 709-713, 1991.
6. Figlin S.A., Belldegrun A., Moldawer N., Zeffren J., DeKernion J.: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J. Clin. Oncol., 10: 414-421, 1992.
7. Fossa S.D., Martinelli G., Otto U., Schneider G., Wander H., Oberling F.: Recombinant interferon alpha-2 with or without vinblastine in metastatic renal cell carcinoma: results of a European multicenter phase III study. Ann. Oncolol., 3: 301-305, 1992.
8. Hrushesky W.J.M., von Roemeling R., Lanning R.M., Rabatin J.T.: Circadian-shaped infusion of floxuridine for progressive metastatic renal cell carcinoma. J. Clin. Oncol., 8: 1504-1513, 1990.
9. Merrouche Y., Negrier S., Lanier F., Rbattu P., Bombaron P., Thill L.: Phase II study of continuous circadian infusion FUDR in metastatic renal cell cancer (Abstract). Eur. J. Cancer, 27(Suppl 2): 99, 1991.
10. Muss H.B., Costanzi J.J., Leavitt R., Williams R.D., Kempf R.A., Pollard R.: Recombinant alpha interferon in renal cell carcinoma: a randomized trial of two routes of administration. J. Clin. Oncol., 5: 286-291, 1987.
11. Neidhart J.A., Anderson S.A., Harris E., Rinehart J.J., Lazslo J., Dexteus F.H.: Vinblastine fails to improve response of renal cell cancer to interferon alpha-1: high response rate in patients with pulmonary metastases. J. Clin. Oncol., 9: 832-837, 1991.
12. Richards F., Cooper M.R., Jackson D.V., Powell B.L., White D.R., Nuss H.B.: Continuous 5-day intravenous FUDR infusion for renal cell carcinoma: a phase I-II trial of the Piedmont Oncology Association (Abstract). Proc. Am. Soc. Clin. Oncol., 10: 70, 1991.
13. Rosenberg S.A., Lotze M.T., Mule J.J.: New approaches in the immunotherapy of cancer using interleukin-2. Ann. Inter. Med., 108: 853-864, 1988.
14. Von Roemeling R., Hrushesky W.J.M.: Circadian pattern of continuous FUDR infusion reduces toxicities. In: Advances in chronobiology, Pauly J.E., Scheving L.E. (Eds), part B, New York, Allen R. Liss, 357-373, 1987.
15. West W.H., Tauer K.W., Yannelli J.F., Marshall G.D., Orr D.W., Thurmann G.R., Oldham R.K.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med., 316: 898-905, 1987.
16. Wilkinson B.M., Stagg R., Grobman B., Carroll P., Venook A.: A phase II study of constant rate FUDR infusion in patients with metastatic renal cell cancer (Abstract). Proc. Am. Soc. Clin. Oncol., 9: 139, 1990.